Better Diabetes Control With Novel Basal Insulins

Slides:

Advertisements

Similar presentations

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.

Advertisements

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.

ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.

Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.

What's New in Basal Insulin for Diabetes

Short-, Intermediate-, Long-Acting Insulins

Updates and Perspectives in Diabetic Dyslipidemia

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

Current Dyslipidemia Management Guidelines Residual Risk.

Special Consideration in Insulin Therapy

Faster-Acting Insulins

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

Using the AGP to Standardize Glucose Reporting

The Next Generation of Basal Insulins

Global Projections for Diabetes:

Insulin Innovation.

Insulin/GLP-1 Agonist Combinations

Insulin Intensification Strategies in Later-Stage Type 2 Diabetes Mellitus.

SGLT2 Inhibitors in Phase 3 Trials

How Early Should Basal Insulin Be Used in T2D Management?

Novel Concentrated Insulins: What Benefits and for Which Patients?

Examining CV Effects of Basal Insulin Therapy

What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?

Innovative Insulin Combinations: A New strategy for the Person With T2DM.

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Metabolically Healthy Patients With Obesity

Emerging Basal Insulins for Diabetes

GLP-1 Receptor Agonists: How Early Is Appropriate?

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Faster-Acting Insulins

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

Insulin/GLP-1 Agonist Combinations

Insulin Innovation.

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

The Research Question Does self monitoring of blood glucose (SMBG) in patients with non-insulin treated type 2 diabetes improve glycemia or quality of.

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

LEADER One Year On.

Predictive Low Glucose Suspend (PLGS)

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Novel Approaches to T1D Management

Aspirin and Cardioprevention in 2018

T2DM Management.

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

Modern Advances in Glucose Monitoring

Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.

Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

Dual SGLT1/SGLT2 Inhibition in T1D

Advancements in Glucose Monitoring

Insulin Innovation.

Statins, Obesity, and Hyperlipidemia

PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH

COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?

Add-On Therapy to Insulin in T1DM Management

Improving Effective Basal Insulin Use in Clinical Practice

Are All Novel Insulins Proven to Be Equally Safe?

2015 EASD In Review: CV Risk management in t2dm

Real-World Evidence.

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future

Fixed-Ratio Combination Therapy in T2DM

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

Emerging Basal Insulins for Diabetes

Fresh perspectives ON BASAL Insulins in diabetes care

Time course of daily basal and mealtime insulin dose (A), glycated hemoglobin (B), laboratory-measured clinic FPG (C), prebreakfast SMPG (D), SMPG profiles.

The Power of As-Treated Analyses

The Challenge of Insulin Titration

Presentation transcript:

Better Diabetes Control With Novel Basal Insulins

Program Overview

Why Next-Generation Basal Insulins Were Developed

Next-Generation Basal Insulins Currently Licensed

Patients Who Will Benefit Most From Next-Generation Basal Insulins

Benefits for Primary Care Physicians

Continuum of Clinical Research: RCTs and RWE

RCTs Do Not Represent Most Patients With T2DM

Summary of BEGIN and EDITION Trials in People With T2DM

BEGIN and EDITION Trials for Deg-100 and Gla-300

RWE for Gla-300: DELIVER Studies

Pragmatic Trials

Pragmatic Trials With Deg-100 and Gla-300

Comparing Deg-100 and Gla-300

BRIGHT: Head-To-Head Comparison of Gla-300 and Deg-100

BRIGHT: Study Endpoints and Glycemic Targets

BRIGHT: Baseline Characteristics

BRIGHT: Primary Endpoint: Glycemic Control

BRIGHT: FPG and SMBG Reduction

BRIGHT: 8-Point SMBG and Variability Profiles

BRIGHT: Anytime (24 h) Hypoglycemia

BRIGHT: Nocturnal (00:00 to 06:00 h) Hypoglycemia

BRIGHT: TEAEs

BRIGHT: Insulin Dosage and Body Weight Over 24 Weeks

BRIGHT: Results Summary

BRIGHT: Results Summary (cont)

BRIGHT: Key Messages for Primary Care

RWE for Second-Generation Basal Insulins

Limitations and Future of RWE

Conclusions

BRIGHT Study

Abbreviations

Abbreviations (cont)